PL353656A1 - Preparation containing amino acids and riboflavin, useful in reducing toxic effects of a treatment by means of cytotoxic drugs - Google Patents

Preparation containing amino acids and riboflavin, useful in reducing toxic effects of a treatment by means of cytotoxic drugs

Info

Publication number
PL353656A1
PL353656A1 PL02353656A PL35365602A PL353656A1 PL 353656 A1 PL353656 A1 PL 353656A1 PL 02353656 A PL02353656 A PL 02353656A PL 35365602 A PL35365602 A PL 35365602A PL 353656 A1 PL353656 A1 PL 353656A1
Authority
PL
Poland
Prior art keywords
amino acids
riboflavin
useful
treatment
preparation containing
Prior art date
Application number
PL02353656A
Other languages
English (en)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Publication of PL353656A1 publication Critical patent/PL353656A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL02353656A 2001-11-27 2002-04-26 Preparation containing amino acids and riboflavin, useful in reducing toxic effects of a treatment by means of cytotoxic drugs PL353656A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/995,010 US20030105104A1 (en) 2001-11-27 2001-11-27 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy

Publications (1)

Publication Number Publication Date
PL353656A1 true PL353656A1 (en) 2003-06-02

Family

ID=25541300

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02353656A PL353656A1 (en) 2001-11-27 2002-04-26 Preparation containing amino acids and riboflavin, useful in reducing toxic effects of a treatment by means of cytotoxic drugs

Country Status (21)

Country Link
US (2) US20030105104A1 (https=)
EP (1) EP1450781B1 (https=)
JP (1) JP4614660B2 (https=)
KR (1) KR100953483B1 (https=)
CN (1) CN100358527C (https=)
AT (1) ATE330595T1 (https=)
BR (1) BR0214430A (https=)
CA (1) CA2468133C (https=)
DE (1) DE60212693T2 (https=)
EA (1) EA009516B1 (https=)
HU (1) HU230986B1 (https=)
IL (2) IL162141A0 (https=)
MX (1) MXPA04004994A (https=)
NO (1) NO332858B1 (https=)
NZ (1) NZ532833A (https=)
PL (1) PL353656A1 (https=)
RO (1) RO121173B1 (https=)
SI (1) SI21542A (https=)
UA (1) UA78977C2 (https=)
WO (1) WO2003045372A1 (https=)
ZA (1) ZA200404115B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293335A1 (en) * 2002-08-02 2006-12-28 Qishou Xu Riboflavin derivative and its manufacture and uses
US20070248693A1 (en) * 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
RU2240788C1 (ru) * 2003-09-09 2004-11-27 Воронежская государственная медицинская академия им. Н.Н. Бурденко Детоксикационное средство
SG158073A1 (en) 2004-11-26 2010-01-29 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
WO2008008084A2 (en) * 2005-09-19 2008-01-17 Cdm Optics, Inc. Task-based imaging systems
MY163134A (en) * 2006-03-15 2017-08-15 Suntory Holdings Ltd Composition containing riboflavin and sesamin-class compounds
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
WO2008105384A1 (ja) * 2007-02-26 2008-09-04 Kyowa Hakko Bio Co., Ltd. シトルリン含有錠剤
JP5591533B2 (ja) 2007-03-15 2014-09-17 サントリーホールディングス株式会社 抗疲労剤
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
EP3011843A1 (en) 2008-09-19 2016-04-27 Nestec S.A. Nutritional support of the immune system during anti-cancer treatment
AU2014200578B2 (en) * 2008-09-19 2016-08-11 Société des Produits Nestlé S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
CA2757373C (en) 2009-04-03 2018-05-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
EA201691430A1 (ru) 2009-06-08 2017-02-28 ЮСиЭл БИЗНЕС ПиЭлСи Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
EP2397458A1 (en) * 2010-06-21 2011-12-21 Lunamed AG Organic salts and co-crystals of phenylbutyric acid
CN104997803B (zh) * 2010-07-22 2019-07-09 雷文制药有限公司 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法和组合物
KR101758424B1 (ko) 2010-09-24 2017-07-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
MX360062B (es) 2010-10-06 2018-10-22 Ocera Therapeutics Inc Metodos de elaboracion de fenilacetato de l-ornitina.
RU2623878C2 (ru) 2010-12-10 2017-06-29 Броади Хэлс Сайенсис, Эл Эл Си Применение жасмоната для лечения нарушения функции мочевого пузыря
JP6090836B2 (ja) * 2011-02-17 2017-03-08 Ｅａファーマ株式会社 化学療法剤の抗腫瘍活性増強剤
AU2012278813B2 (en) * 2011-07-07 2016-09-08 Research Cancer Institute Of America Systems, methods, and formulations for treating cancer
KR101969199B1 (ko) 2013-03-11 2019-04-15 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 폐 기능의 개선 및 방사선 유발된 폐 합병증의 예방 및/또는 치료를 위한 물질 및 방법
JP6742904B2 (ja) * 2013-11-08 2020-08-19 レガシー ヘルスケア リミテッド ガンおよびガン共存症の治療に使用するための組成物
JP6598425B2 (ja) * 2014-02-27 2019-10-30 花王株式会社 疲労の評価方法
US10039735B2 (en) 2014-11-24 2018-08-07 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN105495582A (zh) * 2015-12-11 2016-04-20 北京康比特体育科技股份有限公司 一款抗疲劳、促恢复的保健食品氨基酸组合物
WO2018208677A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
JPS58126767A (ja) * 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
ATE54826T1 (de) * 1985-10-23 1990-08-15 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
US5045468A (en) * 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
DK0421309T4 (da) * 1989-10-02 2003-04-22 Associated British Foods Plc Proteinhydrolysater
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
WO1994014458A1 (en) * 1992-12-23 1994-07-07 Abbott Laboratories Medical foods for the nutritional support of infant/toddler metabolic diseases
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
FR2705765B1 (fr) * 1993-04-29 1995-08-18 Eurofours Sa Porte de four.
NZ248605A (en) * 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
US5547927A (en) * 1993-05-28 1996-08-20 Abbott Laboratories Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5776913A (en) * 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
ATE310505T1 (de) * 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität
US5817927A (en) * 1997-04-11 1998-10-06 Betzdearborn Inc. Method and apparatus for monitoring water process equipment
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
EP1062879B1 (en) 1999-06-26 2003-08-27 B. Braun Melsungen Ag Aqueous solution for the parenteral nutrition
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US6377094B1 (en) * 2002-03-25 2002-04-23 Oak Technology, Inc. Arbitrary waveform synthesizer using a free-running ring oscillator

Also Published As

Publication number Publication date
EA200400737A1 (ru) 2004-12-30
HU230986B1 (hu) 2019-08-28
KR20040065565A (ko) 2004-07-22
SI21542A (sl) 2005-02-28
US7427619B2 (en) 2008-09-23
MXPA04004994A (es) 2005-04-08
DE60212693T2 (de) 2007-07-05
DE60212693D1 (de) 2006-08-03
EP1450781A1 (en) 2004-09-01
JP4614660B2 (ja) 2011-01-19
NZ532833A (en) 2006-12-22
KR100953483B1 (ko) 2010-04-16
CN1596109A (zh) 2005-03-16
JP2005518361A (ja) 2005-06-23
RO121173B1 (ro) 2007-01-30
BR0214430A (pt) 2004-11-03
CN100358527C (zh) 2008-01-02
CA2468133C (en) 2011-02-22
ATE330595T1 (de) 2006-07-15
CA2468133A1 (en) 2003-06-05
IL162141A (en) 2009-05-04
ZA200404115B (en) 2005-11-30
EA009516B1 (ru) 2008-02-28
IL162141A0 (en) 2005-11-20
US20050182064A1 (en) 2005-08-18
HUP0402240A2 (hu) 2005-02-28
UA78977C2 (en) 2007-05-10
AU2002352843A1 (en) 2003-06-10
EP1450781B1 (en) 2006-06-21
NO332858B1 (no) 2013-01-21
HUP0402240A3 (en) 2012-09-28
US20030105104A1 (en) 2003-06-05
NO20042364L (no) 2004-06-07
WO2003045372A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
PL353656A1 (en) Preparation containing amino acids and riboflavin, useful in reducing toxic effects of a treatment by means of cytotoxic drugs
WO2001027109A3 (de) Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate
PL365783A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2002043765A3 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
EP1061915A4 (en) PHARMACEUTICAL FORMULATIONS OF TAXANES
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
IL121160A0 (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO2002013873A3 (en) P97-active agent conjugates and their methods of use
EA200600877A1 (ru) Наночастицы для доставки лекарств
WO2004104005A3 (en) Immunosuppressive effects of pteridine derivatives
CA2514224A1 (en) Liquid pharmaceutical formulations of palonosetron
WO2004005324A3 (en) Peptide composition for treatment of sexual dysfunction
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
MY134690A (en) Antitumor therapy comprising distamycin derivatives.
FR12C0064I2 (fr) Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
AU3278800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
AU2003218141A8 (en) Potent, simplified derivatives of immunosuppressive agents
MX2023013301A (es) Una pluralidad de particulas tasquinimod y su uso.
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
ECSP982396A (es) Composiciones que contienen tetrahidrolipstatina
WO2001035946A3 (en) Intranasal administration of raloxifene and tamoxifen

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)